Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: Upjohn UK Limited, Sandwich, Kent, CT13 9NJ, United Kingdom
RELPAX 20 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. Round, convex orange tablets debossed with ‘REP 20’ on one side and ‘Pfizer’ on the other. |
Each film-coated tablet contains 20 mg eletriptan (as hydrobromide).
Excipients with known effect: Each film-coated tablet contains 23 mg lactose and 0.036 mg Sunset yellow.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Eletriptan |
Eletriptan is a selective agonist at the vascular 5-HT1B and neuronal 5-HT1D receptors. Eletriptan also exhibits high affinity for the 5-HT1F receptor which may contribute to its anti-migraine mechanism of action. |
| List of Excipients |
|---|
|
Core Tablet: Microcrystalline cellulose Film Coat: Titanium dioxide (E171) |
Opaque PVC/Aclar/Aluminium blister packs containing 2, 3, 4, 5, 6, 10, 18, 30 and 100 tablets.
HDPE bottles with child-resistant HDPE/PP closures containing 30 and 100 tablets.
Not all pack sizes may be marketed.
Upjohn UK Limited, Sandwich, Kent, CT13 9NJ, United Kingdom
PL 50622/0053
Date of First Authorisation: 12 February 2001
Date of Last Renewal: 12 February 2011
| Drug | Countries | |
|---|---|---|
| RELPAX | Austria, Australia, Canada, Germany, Spain, France, Hong Kong, Croatia, Ireland, Italy, Japan, Mexico, Netherlands, New Zealand, Poland, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
